International Medicine and Health Guidance News ›› 2025, Vol. 31 ›› Issue (8): 1260-1265.DOI: 10.3760/cma.j.cn441417-20241118-08007
• New Medical Advances • Previous Articles Next Articles
Research progress of thymidylate synthase gene in tumorigenesis and development
Hong Jinquan1, Huang Zhenyu2, Huang Huiwen3, Huang Haobo3
1 Department of Anesthesia, The Second Affiliated Hospital, Fujian Medical University, Quanzhou 362000, China; 2 School of Food and Bioengineering, Fujian Polytechnic Normal University, Fuzhou 350300, China; 3 Department of Blood Transfusion, Fujian Medical University Union Hospital, Fuzhou 350001, China
Received:
2024-11-18
Online:
2025-04-15
Published:
2025-04-20
Contact:
Huang Haobo, Email: huanghaobo1981@163.com
Supported by:
Joint Fund for Innovation of Science and Technology in Fujian province (2019Y9050)
胸苷酸合成酶基因在肿瘤发生发展中的研究进展
洪金全1 黄震宇2 黄惠炆3 黄豪博3
1福建医科大学附属第二医院麻醉科,泉州 362000;2福建技术师范学院食品与生物工程学院,福州 350300;3福建医科大学附属协和医院输血科,福州 350001
通讯作者:
黄豪博,Email:huanghaobo1981@163.com
基金资助:
福建省科技创新联合资金(2019Y9050)
Hong Jinquan, Huang Zhenyu, Huang Huiwen, Huang Haobo.
Research progress of thymidylate synthase gene in tumorigenesis and development [J]. International Medicine and Health Guidance News, 2025, 31(8): 1260-1265.
洪金全 黄震宇 黄惠炆 黄豪博.
胸苷酸合成酶基因在肿瘤发生发展中的研究进展 [J]. 国际医药卫生导报, 2025, 31(8): 1260-1265.
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.imhgn.com/EN/10.3760/cma.j.cn441417-20241118-08007
[1] Wilson PM, Danenberg PV, Johnston PG, et al. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy[J]. Nat Rev Clin Oncol, 2014,11(5):282-298. DOI: 10.1038/nrclinonc.2014.51. [2] Zhang F, Ye J, Guo W, et al. TYMS-TM4SF4 axis promotes the progression of colorectal cancer by EMT and upregulating stem cell marker[J]. Am J Cancer Res, 2022,12(3):1009-1026. [3] Ramadan RA, Moghazy TF, Hafez R, et al. Significance of expression of pyrimidine metabolizing genes in colon cancer[J]. Arab J Gastroenterol, 2020,21(3):189-193. DOI: 10.1016/j.ajg.2020.07.006. [4] Jiang L, Li S, Yuan M, et al. Genetic variants in the Folic acid metabolic pathway genes predict outcomes of metastatic colorectal cancer patients receiving first-line chemotherapy[J]. J Cancer, 2020,11(22):6507-6515. DOI: 10.7150/jca.44580. [5] Pereira MA, Ramos MFKP, Dias AR, et al. Immunohistochemical expression of thymidylate synthase and prognosis in gastric cancer patients submitted to fluoropyrimidine-based chemotherapy[J]. Chin J Cancer Res, 2018,30(5):526-536. DOI: 10.21147/j.issn.1000-9604.2018.05.06. [6] Song S, Tian B, Zhang M, et al. Diagnostic and prognostic value of thymidylate synthase expression in breast cancer[J]. Clin Exp Pharmacol Physiol, 2021,48(2):279-287. DOI: 10.1111/1440-1681.13415. [7] Wang L, Wu Z, Wang Y, et al. TYMS knockdown suppresses cells proliferation, promotes ferroptosis via Inhibits PI3K/Akt/mTOR signaling pathway activation in triple negative breast cancer[J]. Cell Biochem Biophys, 2024,82(3):2717-2726. DOI: 10.1007/s12013-024-01388-5. [8] Rahimi Z, Bozorgi Zarini M, Rahimi Z, et al. Variants of genes involved in metabolism of folate among patients with breast cancer: association of TYMS 3R allele with susceptibility to breast cancer and metastasis[J]. Iran J Pathol, 2021,16(1):62-68. DOI: 10.30699/ijp.2020. 117676.2283. [9] 周文,王佳丽,谭碧波,等. ERCC1、TYMS和RRM1在宫颈癌组织中的表达及与化疗疗效的关系[J]. 中国癌症防治杂志,2019,11(6):513-517. DOI:10.3969/j.issn.1674-5671. 2019.06.12. [10] Rakic A, Anicic R, Rakic M, et al. Integrated bioinformatics investigation of novel biomarkers of uterine leiomyosarcoma diagnosis and outcome[J]. J Pers Med, 2023,13(6):985. DOI: 10.3390/jpm13060985. [11] Donner DB, Nakakura EK, Venook AP, et al. High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma[J]. PLoS One, 2019,14(7):e0219469. DOI: 10.1371/journal.pone.0219469. [12] Gandhi M, Groß M, Holler JM, et al. The lncRNA lincNMR regulates nucleotide metabolism via a YBX1 - RRM2 axis in cancer[J]. Nat Commun, 2020,11(1):3214. DOI: 10.1038/s41467-020-17007-9. [13] Li S, Zhao J, Lv L, et al. Identification and validation of TYMS as a potential biomarker for risk of metastasis development in hepatocellular carcinoma[J]. Front Oncol, 2021,11:762821. DOI: 10.3389/fonc.2021.762821. [14] Chamizo C, Zazo S, Dómine M, et al. Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer[J]. BMC Pulm Med, 2015,15:132. DOI: 10.1186/s12890-015- 0132-x. [15] Kulda V, Hrda K, Houdek Z, et al. Predictive significance of thymidylate synthase expression in non-small cell lung cancer[J]. Anticancer Res, 2017,37(12):6953-6958. DOI: 10.21873/anticanres.12161. [16] Yin Y, Li D, He M, et al. The identification of hub biomarkers and pathways in lung cancer and prognostic evaluation[J]. Transl Cancer Res, 2022,11(8):2622-2635. DOI: 10.21037/tcr-22-245. [17] Li Y, Li X, Dai H, et al. Thymidylate synthase was associated with patient prognosis and the response to adjuvant therapy in bladder cancer[J]. BJU Int, 2009,103(4):547-552. DOI: 10.1111/j.1464-410X. 2008.08099.x. [18] Zhang S, Yan L, Cui C, et al. Identification of TYMS as a promoting factor of retroperitoneal liposarcoma progression: bioinformatics analysis and biological evidence[J]. Oncol Rep, 2020,44(2):565-576. DOI: 10.3892/or.2020.7635. [19] Zhao M, Tan B, Dai X, et al. DHFR/TYMS are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide[J]. Eur J Pharmacol, 2019,863:172665. DOI: 10.1016/j.ejphar.2019.172665. [20] Wu M, Ou-Yang DJ, Wei B, et al. A prognostic model of differentiated thyroid cancer based on up-regulated glycolysis-related genes[J]. Front Endocrinol (Lausanne), 2022,13:775278. DOI: 10.3389/fendo.2022.775278. [21] Al-Sheikh A, Yousef AM, Alshamaseen D, et al. Effects of thymidylate synthase polymorphisms on toxicities associated with high-dose methotrexate in childhood acute lymphoblastic leukemia[J]. Cancer Chemother Pharmacol, 2021,87(3):379-385. DOI: 10.1007/s00280-020-04197-8. [22] Chen Q, Pu N, Yin H, et al. A metabolism-relevant signature as a predictor for prognosis and therapeutic response in pancreatic cancer[J]. Exp Biol Med (Maywood), 2022,247(2):120-130. DOI: 10.1177/15353702211049220. [23] Emelyanova M, Pokataev I, Shashkov I, et al. TYMS 3'-UTR polymorphism: a novel association with FOLFIRINOX-induced neurotoxicity in pancreatic cancer patients[J]. Pharmaceutics, 2021,14(1):77. DOI: 10.3390/pharmaceutics14010077. [24] Tsyganov MM, Rodionov EO, Ibragimova MK, et al. Personalized prescription of chemotherapy based on assessment of mRNA expression of BRCA1, RRM1, ERCC1, TOP1, TOP2α, TUBβ3, TYMS, and GSTP1 genes in tumors compared to standard chemotherapy in the treatment of non-small-cell lung cancer[J]. J Pers Med, 2022,12(10):1647. DOI: 10.3390/jpm12101647. [25] Kurasaka C, Ogino Y, Sato A. Molecular mechanisms and tumor biological aspects of 5-fluorouracil resistance in HCT116 human colorectal cancer cells[J]. Int J Mol Sci, 2021,22(6):2916. DOI: 10.3390/ijms22062916. [26] Ciszewski WM, Chmielewska-Kassassir M, Wozniak LA, et al. Thymidylate synthase overexpression drives the invasive phenotype in colon cancer cells[J]. Biomedicines, 2022,10(6):1267. DOI: 10.3390/biomedicines10061267. [27] Yang J, Zhang J, Chen J, et al. Thymidylate synthase promotes esophageal squamous cell carcinoma growth by relieving oxidative stress through activating nuclear factor erythroid 2-related factor 2 expression[J]. PLoS One, 2023,18(9):e0290264. DOI: 10.1371/journal.pone.0290264. [28] Chen Y, Zhang C, Jin S, et al. Pemetrexed induces ROS generation and cellular senescence by attenuating TS-mediated thymidylate metabolism to reverse gefitinib resistance in NSCLC[J]. J Cell Mol Med, 2023,27(14):2032-2044. DOI: 10.1111/jcmm.17799. [29] Sato Y, Tomita M, Soga T, et al. Upregulation of thymidylate synthase induces pemetrexed resistance in malignant pleural mesothelioma[J]. Front Pharmacol, 2021,12:718675. DOI: 10.3389/fphar.2021.718675. [30] Guijarro MV, Nawab A, Dib P, et al. TYMS promotes genomic instability and tumor progression in Ink4a/Arf null background[J]. Oncogene, 2023,42(23):1926-1939. DOI: 10.1038/s41388-023-02694-7. [31] Wan S, Liu Z, Chen Y, et al. MicroRNA-140-3p represses the proliferation, migration, invasion and angiogenesis of lung adenocarcinoma cells via targeting TYMS (thymidylate synthetase)[J]. Bioengineered, 2021,12(2):11959-11977. DOI: 10.1080/21655979.2021.2009422. [32] Mannava S, Grachtchouk V, Wheeler LJ, et al. Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells[J]. Cell Cycle, 2008,7(15):2392-2400. DOI: 10.4161/cc.6390. [33] Zhang S, Liu N, Cao P, et al. LncRNA BC200 promotes the development of EBV-associated nasopharyngeal carcinoma by competitively binding to miR-6834-5p to upregulate TYMS expression[J]. Int J Biol Macromol, 2024,278(Pt 4):134837. DOI: 10.1016/j.ijbiomac.2024.134837. [34] Liang J, Lu T, Chen Z, et al. Mechanisms of resistance to pemetrexed in non-small cell lung cancer[J]. Transl Lung Cancer Res, 2019,8(6):1107-1118. DOI: 10.21037/tlcr.2019.10.14. [35] Honeywell RJ, Ruiz van Haperen VW, Veerman G, et al. Inhibition of thymidylate synthase by 2',2'-difluoro-2'-deoxycytidine (Gemcitabine) and its metabolite 2',2'-difluoro-2'-deoxyuridine[J]. Int J Biochem Cell Biol, 2015,60:73-81. DOI: 10.1016/j.biocel.2014.12.010. [36] Chmielewska-Kassassir M, Sobierajska K, Ciszewski WM, et al. Evening primrose extract modulates TYMS expression via SP1 transcription factor in malignant pleural mesothelioma[J]. Cancers (Basel), 2023,15(20):5003. DOI: 10.3390/cancers15205003. [37] Ciszewski WM, Włodarczyk J, Chmielewska-Kassassir M, et al. Evening primrose seed extract rich in polyphenols modulates the invasiveness of colon cancer cells by regulating the TYMS expression[J]. Food Funct, 2022,13(21):10994-11007. DOI: 10.1039/d2fo01737g. [38] Zhu Z, Liu Y, Zeng J, et al. Diosbulbin C, a novel active ingredient in Dioscorea bulbifera L. extract, inhibits lung cancer cell proliferation by inducing G0/G1 phase cell cycle arrest[J]. BMC Complement Med Ther, 2023,23(1):436. DOI: 10.1186/s12906-023-04245-9. [39] Kim N, Yang C. Sodium butyrate inhibits the expression of thymidylate synthase and induces cell death in colorectal cancer cells[J]. Int J Mol Sci, 2024,25(3):1572. DOI: 10.3390/ijms25031572. |
[1] |
Li Qiang.
Research progress of ultrasound-guided radiofrequency ablation in treatment of thyroid micropapillary carcinoma [J]. International Medicine and Health Guidance News, 2025, 31(8): 1258-1260. |
[2] |
Jiang Meng, Zhao Jingru, Liu Hui, Liu Qingxin.
Research progress on autophagy and ischemic cerebrovascular diseases [J]. International Medicine and Health Guidance News, 2025, 31(8): 1265-1269. |
[3] |
Liu Hanqing, Sun Yinping, Zhao Qiang, Ren Shuai.
Research progress on neoadjuvant immunotherapy for MSI-H/dMMR subtype patients with locally advanced colorectal cancer [J]. International Medicine and Health Guidance News, 2025, 31(8): 1270-1274. |
[4] |
Wen Na, Zhang Xuan.
Mechanism of treating vulvovaginal candidiasis with Honghe Fujie liquid [J]. International Medicine and Health Guidance News, 2025, 31(8): 1292-1296. |
[5] |
Shi Hanjin, Ma Huixuan, Wang Yuanping.
Mechanism of Xinkeshu in treatment of coronary heart disease based on network pharmacology and molecular docking technology [J]. International Medicine and Health Guidance News, 2025, 31(7): 1140-1148. |
[6] |
Cao Shanmian, Zheng Xiaoying, Zhu Hongrui.
Effect of Omaha system-based extended care intervention in post-hospital care for premature infants with low birth weight [J]. International Medicine and Health Guidance News, 2025, 31(7): 1223-1227. |
[7] |
Zhu Peng, Tang Wenling, Qin Gang.
Research progress on microRNA function and clinical value in colorectal cancer [J]. International Medicine and Health Guidance News, 2025, 31(6): 886-890. |
[8] |
Pan Wenxin, Jiang Weiwei.
Advances in research on impact of colonoscopy timing on prognosis of patients with ischemic colitis [J]. International Medicine and Health Guidance News, 2025, 31(6): 914-917. |
[9] |
Zhang Ziyi, Sun Dakang.
Research progress on mechanism of TRIM22 against HIV-1 [J]. International Medicine and Health Guidance News, 2025, 31(6): 918-922. |
[10] |
Yi Wei, Mi Qianqian, Zhao Jie, Li Boyu, Wang Dan.
Application of color Doppler flow imaging in retrobulbar hemodynamic testing [J]. International Medicine and Health Guidance News, 2025, 31(6): 922-926. |
[11] |
Chen Xiuzhu, Zhang Kai, Wei Yanxiao, Cong Chenyang.
Drug therapy for thyroid associated ophthalmopathy [J]. International Medicine and Health Guidance News, 2025, 31(6): 927-929. |
[12] |
Li Xiaotong, Yu Shengqiang.
Research progress of tubule-derived exosomes in renal fibrosis [J]. International Medicine and Health Guidance News, 2025, 31(5): 712-718. |
[13] |
Zhang Han, Sun Ting, Wang Yanfei, Zhang Xiaolin, Che Juan.
Research progress of post-transplantation lymphoproliferative disease in children with adenotonsillar hypertrophy [J]. International Medicine and Health Guidance News, 2025, 31(5): 752-757. |
[14] |
Mo Jiachan, Fan Wanfeng, Jiang Xingyue.
Application status and progress of MRI based radiomics in pituitary adenoma [J]. International Medicine and Health Guidance News, 2025, 31(5): 757-760. |
[15] |
Liu Weifeng, Guo Yuan, Tang Wenjie, Yang Ruimeng, Fan Hao, Wei Xinhua.
"Medical + X" talent training mode for development of comprehensive capability of medical imaging graduate students [J]. International Medicine and Health Guidance News, 2025, 31(4): 530-534. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||